STAT

3 China biotech stories to watch in 2019

In 2018, biotech in China generated relentless news. What's next for 2019?

As 2019 begins, STAT reporters are taking a look at the stories they’re most eager to track during the year. Find all our “three to watch” series here

This past year has often felt like the year that China’s biotech sector finally arrived. After years of punching below its weight, in 2018 the industry generated relentless news, milestones, and investment going in both directions across the Pacific.

Stai leggendo un'anteprima, registrati per continuare a leggere.

Altro da STAT

STAT1 min lettiPolitics
STAT Plus: Pharmalittle: U.S. Chamber Wants Transparency Around Covid-19 Vaccines; EU To Pump Billions Into Vaccine Deals
The U.S. Chamber of Commerce has suggested that more transparency is needed surrounding the Covid-19 vaccine deals that are being struck between drug makers and governments.
STAT1 min letti
STAT Plus: Pharmalittle: Gilead Faces Remdesivir Production Challenges; Will Scientists Run Out Of Covid-19 Trial Patients?
Gilead faces the challenge of scaling up production of remdesivir, its experimental #Covid19 drug that the whole world may want.
STAT1 min letti
STAT Plus: Pharmalittle: Trump Officials Maintain Covid-19 Vaccine Won’t Be Influenced By Politics; Novartis Pays $678 Million To Settle Kickback Charges
To assuage some of that concern, the agency released a guidance that outlines conditions for approving a Covid-19 vaccine.